Antifungal susceptibility testing of a 10-year collection of Candida spp. isolated from patients with candidemia

Journal of Chemotherapy

Volumn 23, Issue 2, 2011, Pages 92-96

  Iatta, R ^a   Caggiano, G ^a   Cuna, T ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

Antifungal susceptibility; Candidemia; CLSI reference broth microdilution method

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; CASPOFUNGIN; FLUCONAZOLE; ITRACONAZOLE; POSACONAZOLE; VORICONAZOLE;

ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BLOODSTREAM INFECTION; BROTH DILUTION; CANDIDA ALBICANS; CANDIDA DUBLINIENSIS; CANDIDA GLABRATA; CANDIDA INTERMEDIA; CANDIDA KRUSEI; CANDIDA NORVEGENSIS; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDEMIA; CATHETER INFECTION; CLAVISPORA LUSITANIAE; CONTROLLED STUDY; FUNGAL STRAIN; FUNGUS IDENTIFICATION; KLUYVEROMYCES MARXIANUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PICHIA ANOMALA; PICHIA GUILLIERMONDII; RETROSPECTIVE STUDY;

EID: 80052745930     PISSN: 1120009X     EISSN: 19739478     Source Type: Journal    
DOI: 10.1179/joc.2011.23.2.92     Document Type: Article

References (25)

1. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39 (3): 309-317.
2. Bouza E, Munoz P. Epidemiology of candidemia in intensive care units. Int J Antimicrob Agents 2008; 32 Suppl 2: 87-91.
3. Pappas PG, Kauffman CA, Andes D, Benjamin DK Jr, Calandra TF, Edwards JE Jr et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48 (5): 503-535.
4. Lai CC, Tan CK, Huang YT, Shao PL, Hsueh PR. Current challenges in the management of invasive fungal infections. J Infect Chemother 2008; 14 (2): 77-85.
5. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007; 20 (1): 133-63.
6. Sobel JD. The emergence of non-a/bicans Candida species as causes of invasive candidiasis and candidemia. Curr Infct Dis Rep 2006; 8 (6): 427-433.
7. Horn DL, Neofytos D, Anaissie EJ, Fishman JA, Steinbach WJ, Olyaei AJ et al. Epidemiology and outcome of candidemia in 2019 patients: Data from the prospective antifungal therapy alliance registry. Clin Infect Dis 2009; 48 (12): 1695-1703.
8. Tortorano AM, Peman J, Bernhardt H, Klingspor L, Kibbler CC, Faure O et al. Epidemiology of candidaemia in Europe: Results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study. Eur J Clin Microbiol Infect Dis 2004; 23 (4): 317-322.
9. Bassetti M, Righi E, Costa A, Fasce R, Molinari MP, Rosso R et al. Epidemiological trends in nosocomial candidemia in intensive care. BMC Infect Dis 2006; 6: 21.
10. Bedini A, Venturelli C, Mussini C, Guaraldi G, Codeluppi M, Borghi V et al. Epidemiology of candidaemia and antifungal susceptibility patterns in an Italian tertiary-care hospital. Clin Microbiol Infect 2005; 12 (1): 75-80.
11. Pfaller MA, Diekema DJ, Messer SA, Boyken L, Hollis RJ. Activities of fluconazole and voriconazole against 1,586 recent clinical isolates of Can- dida species determined by Broth microdilution, disk diffusion, and Etest methods: report from the ARTEMIS Global Antifungal Suscetibility Program, 2001. J Clin Microbiol 2003; 41 (4): 1440-1446.
12. Yang YL, Ho YA, Cheng HH, Ho M, Lo HJ. Susceptibilities of Candida species to amphotericin B and fluconazole: the emergence of fluconazole resistance in Candida tropicalis. Infect Control Hosp Epidemiol 2004; 25 (1): 60-64.
13. Maki DG, Weise CE, Sarafin HW. A semiquantitative culture method for identifying intravenous-catheter-related infection. N Engl J Med 1977; 296 (23): 1305-1309.
14. Hazen KC, and Howell SA. Candida, Cryptococcus, and other yeasts of medical importance. In Murray PR, Baron EJ, Jorgensen JH et al, eds. Manual of Clinical Microbiology, 9th edn. Washington DC, ASM Press 2007; 1762-1788.
15. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts - Second Edition: Approved Standard, M27-A2. NCCLS, Villanova, PA, USA, 2002.
16. Cuenca-Estrella M, Rodriguez D, Almirante B, Morgan J, Planes AM, Almela M et al. In vitro susceptibilities of bloodstream isolates of Candida species to six antifungal agents: results from a population-based active surveillance programme, Barcelona, Spain, 2002-2003. J Antimicrob Che- mother 2005; 55 (2): 194-199.
17. Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts - Third Informational Supplement, M27-S3. CLSI, Wayne, PA, USA, 2008
18. Diekema DJ, Messer SA, Boyken LB, Hollis RJ, Kroeger J, Tendolkar S et al. In vitro activity of seven systemically active antifungal agents against a large global rare Candida species as determined by CLSI broth microdilu-tion methods. J Clin Microbiol 2009; 47 (10): 3170-3177.
19. Ben-Ami R, Weinberger M, Orni-Wasserlauff R, Schwartz D, Itzhaki A, Lazarovitch T et al. Time to blood culture positivity as a marker for catheter-related candidemia. J Clin Microbiol 2008; 46 (7): 2222-2226.
20. Mermel LA, Farr BM, Sherertz RJ, Raad II, O'Grady N, Harris JS et al.; Infectious Diseases Society of America; American College of Critical Care Medicine; Society for Healthcare Epidemiology of America. Guidelines for the management of intravascular catheter-related infections. Clin Infect Dis 2001; 32 (9): 1249-1272.
21. Espinel-Ingroff A, Canton E, Peman J, Martin-Mazuelo E. Comparison of anidulafungin MICs determined by the clinical and laboratory standards in- stitute broth microdilution method (M27-A3 document) and Etest for Can dida species isolates. Antimicrob Agents Chemother 2010; 54 (3): 1347-1350.
22. Pfaller MA, Diekema DJ, Gibbs DL, Newell VA, Barton R, Bijie H et al.; Global Antifungal Surveillance Group. Geographic variation in the frequency of isolation and fluconazole and voriconazole susceptibilities of Candida glabrata: an assessment from the ARTEMIS DISK Global Antifungal Surveillance Program. Diagn Microbiol Infect Dis 2010; 67 (2): 162-171.
23. Vandeputte P, Larcher G, Berges T, Renier G, Chabasse D, Bouchara JP. Mechanisms of azole resistance in a clinical isolate of Candida tropi-calis. Antimicrob Agents Chemother 2005; 49 (11): 4608-4615.
24. Morace G, Amato G, Bistoni F, Fadda G, Marone P, Montagna MT et al. A multicenter comparative evaluation of six commercial systems and the National Committee for Clinical Laboratory Standards M27-A broth microdilution method for fluconazole susceptibility testing of Candida species. J Clin Microbiol 2002; 40 (8): 2953-2958.
25. Morace G, Polonelli L; GISIA Group. Voriconazole activity against clinical yeast isolates: A multicenter Italian Study. Int J Antimicrob Agents 2005; 26 (3): 247-253.